NEW
YORK, Sept. 13, 2024 /PRNewswire/ -- Report on
how AI is redefining market landscape- The global exosome
therapeutics market size is estimated to grow by USD 234.7 million from 2024-2028, according to
Technavio. The market is estimated to grow at a CAGR of
16.19% during the forecast period. Increasing
prevalence of chronic diseases is driving market
growth, with a trend towards advanced technology in
exosome collection. However, strict regulatory approval for
exosome therpeutics launches poses a challenge. Key market
players include Aegle Therapeutics, Aethlon Medical Inc., AMS
Biotechnology Europe Ltd., Bio Techne Corp., Capital Biosciences
Inc., Capricor Therapeutics Inc., CILOA SAS, Creative Biolabs,
Cytiva, Everzom, Evotec SE, Evox Therapeutics Ltd., ExoCoBio Co.
Ltd., Inoviq Ltd., Lonza Group Ltd., NanoFCM Co., Ltd, Regeneron
Pharmaceuticals Inc., ReNeuron Group plc, The ExoBiologics Co., and
Thermo Fisher Scientific Inc..
Key insights into market evolution with
AI-powered analysis. Explore trends, segmentation, and growth
drivers- View the snapshot of this report
Exosome Therapeutics
Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
16.19%
|
Market growth
2024-2028
|
USD 234.7
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
15.76
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
30%
|
Key
countries
|
US, Germany, UK, China,
and Japan
|
Key companies
profiled
|
Aegle Therapeutics,
Aethlon Medical Inc., AMS Biotechnology Europe Ltd., Bio Techne
Corp., Capital Biosciences Inc., Capricor Therapeutics Inc., CILOA
SAS, Creative Biolabs, Cytiva, Everzom, Evotec SE, Evox
Therapeutics Ltd., ExoCoBio Co. Ltd., Inoviq Ltd., Lonza Group
Ltd., NanoFCM Co., Ltd, Regeneron Pharmaceuticals Inc., ReNeuron
Group plc, The ExoBiologics Co., and Thermo Fisher Scientific
Inc.
|
Market Driver
The global exosome therapeutics market is experiencing
significant growth due to advancements in exosome collection
technologies. New methods, such as microfluidic devices,
immunoaffinity capture, and continuous-flow systems, enable more
efficient and effective exosome isolation and purification from
complex samples. Microfluidic devices, in particular, provide
high-throughput, efficient exosome isolation using techniques like
deterministic lateral displacement and integrated immune isolation.
These technologies manipulate small fluid volumes through
microchannels with dimensions ranging from tens to hundreds of
micrometers, offering unique functionality not previously possible
with traditional methods. Additionally, nanoparticle tracking
analysis (NTA) is used for exosome tracking in cancer research,
determining concentration and size distribution of particles,
further driving market growth.
Exosome Therapeutics is a rapidly growing field in healthcare,
leveraging the transporting capacity of natural and hybrid exosomes
for therapeutic applications. Exosomes derived from sources like
Mesenchymal Stem Cells in Blood and Body Fluids, such as Urine,
Saliva, Milk, and Dendritic Cells, are being explored for
Immunotherapy, Chemotherapy, and Gene Therapy. Exosomes' small size
and ability to carry Bio Macromolecules and Small Molecules make
them promising for treating various disorders, including Metabolic
Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory
Disorders, Organ Transplantation, Gynecology Disorders, and Blood
Disorders. Exosome-based Therapies are being developed for
Parenteral and Oral administration. The market for Exosome
Therapeutics and Exosome Diagnostics is expanding, with
advancements in Exosome Isolation, Characterization, and Analysis.
Companies are investing in technologies like Scale-X fixed-bed
bioreactors and Extracellular Vesicles to improve Exosome
production. Personalized medicine and FDA approvals for Gene
Therapies and Cell-based Therapies are expected to fuel market
growth. The aging population and the increasing prevalence of
Chronic Wounds further boost demand.
Request Sample of our comprehensive
report now to stay ahead in the AI-driven market evolution!
Market Challenges
- The regulatory approval process for exosome therapeutics is a
significant challenge, with stringent regulations and unpredictable
timelines. Exosomes used in clinical trials must adhere to Good
Manufacturing Practices (GMP), with key issues being the upstream
cell cultivation process, downstream purification process, and
exosome quality control. Vendors must comply with regulatory
requirements and provide safety and efficacy data during clinical
trials. Japan has strict product
approval guidelines in APAC, while technical challenges arise in
other regions during the clinical trial phase. Failure to produce
positive results in one region can burden vendors and negatively
impact other trials, potentially hindering the growth of the global
exosome therapeutics market.
- The Exosome Therapeutics Market holds significant potential in
addressing various health challenges, including chronic diseases
like Alzheimer's, Parkinson's, and cancer. Exosomes, nanosized
particles carrying genetic and protein cargo, offer a promising
solution for molecular diagnosis and drug development. In the face
of infectious diseases and autoimmune conditions, exosome
technology can aid in immune suppression and precision medicine.
Pharmaceutical and biopharmaceutical companies are increasingly
investing in exosome research for drug therapies against
neurodegeneration, cardiovascular dysfunction, and cancer. Key
players in this field include Aethlon Medical. Exosome-based
diagnostics, such as the ExoDx Prostate test and liquid biopsy, are
revolutionizing cancer institutes and diagnostic centers. VA
Healthcare System and instruments/software providers are also
adopting this technology to enhance patient care. Despite these
advancements, challenges persist in standardizing exosome isolation
and characterization, as well as ensuring regulatory
compliance.
Discover how AI is revolutionizing market
trends- Get your access now!
Segment Overview
This exosome therapeutics market report extensively covers
market segmentation by
- Application
- 1.1 Cancer therapies
- 1.2 Autoimmune diseases
- 1.3 Infectious diseases
- 1.4 Others
- Distribution Channel
- 2.1 Hospital pharmacy
- 2.2 Retail pharmacy
- 2.3 Online pharmacy
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Cancer therapies- Exosomes are small
vesicles released by cells that play a significant role in cancer
progression, metastasis, immune response, and therapy resistance.
In cancer therapy, exosomes act as drug transporters, offering
novel strategies for targeted drug delivery. By loading exosomes
with anticancer drugs or nucleic acids, precise targeting of cancer
cells becomes possible, minimizing damage to healthy tissues. With
cancer being a leading cause of mortality, such as the second most
common cause in the US after heart disease, new cases reached
around 1.9 million in the US and 20 million globally in 2023,
resulting in approximately 9.7 million deaths. The increasing
prevalence of cancer necessitates innovative therapies.
Consequently, the growing cancer therapies segment is expected to
fuel the expansion of the global exosome therapeutics market during
the forecast period.
Download a Sample of our
comprehensive report today to discover how AI-driven innovations
are reshaping competitive dynamics
Research Analysis
Exosome Therapeutics refer to the use of exosomes, small
extracellular vesicles, as therapeutic agents for various diseases.
Exosomes can be derived from natural sources such as body fluids
like blood, urine, saliva, milk, and cultured cells like
Mesenchymal Stem Cells and Dendritic Cells. Hybrid exosomes can be
engineered to carry specific therapeutic cargos. Exosome-based
therapeutics hold promise in immunotherapy, chemotherapy, and gene
therapies for chronic diseases like cancer, autoimmune diseases,
and infectious diseases. The market for Exosome Therapeutics and
diagnostics is growing rapidly, with advancements in exosome
isolation, characterization, and analysis using technologies like
Scale-X fixed-bed bioreactors. Personalized medicine and FDA
approvals are expected to further fuel market growth. Exosomes
derived from different sources exhibit distinct characteristics and
therapeutic potential, offering opportunities for targeted
therapies and molecular diagnosis.
Market Research Overview
Exosome Therapeutics refers to the use of exosomes, small
membrane-bound vesicles secreted by various cell types, as
therapeutic agents. Exosomes carry bioactive molecules such as
proteins, lipids, and nucleic acids, making them potential carriers
for various therapeutic modalities. Exosomes can be derived from
various sources, including Natural Exosomes from body fluids like
blood, urine, saliva, milk, and Hybrid Exosomes produced through
the fusion of donor cells and recipient cells. Exosome Therapeutics
hold immense potential in various therapeutic areas such as
Immunotherapy, Chemotherapy, and Gene Therapy. Their transporting
capacity makes them effective in delivering bioactive molecules to
target cells, making them promising candidates for treating
Metabolic Disorders, Oncology, Cardiac Disorders, Neurology,
Inflammatory Disorders, Organ Transplantation, and Gynecology
Disorders. Exosome-based therapeutics are being developed using
various techniques like Parenteral and Oral administration, and are
being explored in Hospitals and Diagnostic Centers for
Neurodegenerative Disorders, Chronic Wounds, and the Elderly
Population. The Exosome diagnostics market is also growing, with
applications in Molecular Diagnosis and Liquid Biopsy kits. Exosome
isolation, characterization, and analysis are crucial steps in the
Exosome value chain, and various techniques like Scale-X fixed-bed
bioreactor, Ultracentrifugation, Precipitation, Chromatography,
Differential centrifugation, Size-exclusion chromatography, and
Immunoaffinity capture are used for this purpose. Exosomes have
multifunctional properties and hold potential in treating Chronic
Diseases, Infectious Diseases, and Autoimmune Diseases, including
Cancer. FDA approvals for Exosome-based therapeutics and Gene
therapies, as well as Cell-based therapies, are expected to drive
the Exosome Therapeutics market. Exosome production is also a focus
area for Pharmaceutical and Biopharmaceutical companies. Exosomes
have emerged as a promising area of research due to their potential
in Drug development and Drug therapies. The Exosome technology is
being explored for its role in Precision medicine and Personalized
medicine, making it a key area of interest for researchers and
healthcare infrastructure.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Cancer Therapies
- Autoimmune Diseases
- Infectious Diseases
- Others
- Distribution Channel
-
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/exosome-therapeutics-market-to-grow-by-usd-234-7-million-from-2024-2028--driven-by-rising-chronic-disease-cases-and-ais-impact-on-market-trends--technavio-302246519.html
SOURCE Technavio